Victrex Rating Reiterated by JPMorgan Chase & Co. (VCT)
Victrex (LON:VCT)‘s stock had its “neutral” rating reaffirmed by equities researchers at JPMorgan Chase & Co. in a research report issued on Wednesday, AnalystRatingsNetwork.com reports. They currently have a GBX 1,550 ($24.87) price target on the stock. JPMorgan Chase & Co.’s price target indicates a potential upside of 0.06% from the company’s current price.
Victrex (LON:VCT) traded up 0.52% during mid-day trading on Wednesday, hitting GBX 1557.00. 104,611 shares of the company’s stock traded hands. Victrex has a 1-year low of GBX 1366.00 and a 1-year high of GBX 1791.00. The stock has a 50-day moving average of GBX 1593. and a 200-day moving average of GBX 1609.. The company’s market cap is £1.311 billion.
A number of other firms have also recently commented on VCT. Analysts at Bank of America Corp. reiterated an “underperform” rating on shares of Victrex in a research note to investors on Wednesday. They now have a GBX 1,400 ($22.46) price target on the stock. Separately, analysts at Nplus1 Brewin reiterated a “hold” rating on shares of Victrex in a research note to investors on Tuesday. They now have a GBX 1,645 ($26.39) price target on the stock. Finally, analysts at N+1 Singer reiterated a “hold” rating on shares of Victrex in a research note to investors on Tuesday. They now have a GBX 1,645 ($26.39) price target on the stock. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of GBX 1,661.54 ($26.66).
Victrex plc is engaged in the manufacturing and selling of high performance polymers. The Company’s business is organized as two business units: Victrex Polymer Solutions (LON:VCT) and Invibio Biomaterial Solutions (Invibio).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.